Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study

K Gagne; P Loiseau; V Dubois; F Dufossé; P Perrier; A Dormoy; I Jollet; V Renac; D Masson; C Picard; X Lafarge; D Hanau; F Quainon; F Delbos; B Coeffic; Léna Absi; J-F Eliaou; V Moalic; M Fort; M de Matteis; I Theodorou; F Hau; A Batho; B Pedron; S Caillat-Zucman; E Marry; N Raus; I Yakoub-Agha; A Cesbron

doi:10.1038/bmt.2014.253

Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study

Bone Marrow Transplant. 2015 Feb;50(2):232-6. doi: 10.1038/bmt.2014.253. Epub 2014 Nov 3.

Authors

K Gagne¹, P Loiseau², V Dubois³, F Dufossé⁴, P Perrier⁵, A Dormoy⁶, I Jollet⁷, V Renac⁸, D Masson⁹, C Picard¹⁰, X Lafarge¹¹, D Hanau¹², F Quainon¹³, F Delbos¹⁴, B Coeffic¹⁵, Léna Absi¹⁶, J-F Eliaou¹⁷, V Moalic¹⁸, M Fort¹⁹, M de Matteis²⁰, I Theodorou²¹, F Hau²², A Batho²³, B Pedron²⁴, S Caillat-Zucman²⁵, E Marry²⁶, N Raus²⁷, I Yakoub-Agha²⁷, A Cesbron²⁸

Affiliations

¹ 1] HLA Laboratory, EFS Nantes, Nantes, France [2] EA4271 EFS Nantes, Nantes, France [3] Labex Transplantex, Université Strasbourg, Strasbourg, France.
² 1] Labex Transplantex, Université Strasbourg, Strasbourg, France [2] HLA Laboratory, Inserm UMR940, AP-HP Paris Saint Louis.
³ HLA Laboratory, EFS Lyon, Lyon, France.
⁴ HLA Laboratory, CHU Lille, Lille, France.
⁵ HLA Laboratory, CHU Nancy, Nancy, France.
⁶ HLA Laboratory, EFS Besançon, Besancon, France.
⁷ HLA Laboratory, EFS Poitiers, Poitiers, France.
⁸ HLA Laboratory, EFS Rennes, Rennes, France.
⁹ HLA Laboratory, EFS Grenoble, Grenoble, France.
¹⁰ HLA Laboratory, UMR 7268 Université Aix-Marseille, EFS Marseille, Marseille, France.
¹¹ HLA Laboratory, EFS Bordeaux, Bordeaux, France.
¹² HLA Laboratory, EFS Strasbourg, Strasbourg, France.
¹³ HLA Laboratory, EFS Clermont-Ferrand, Clermont-Ferrand, France.
¹⁴ HLA Laboratory, AP-HP Paris Créteil, Paris, France.
¹⁵ HLA Laboratory, EFS Angers, Angers, France.
¹⁶ HLA Laboratory, EFS Saint-Etienne, Saint-Etienne, France.
¹⁷ 1] HLA Laboratory, CHU Montpellier, Montpellier, France [2] Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI), Paris, France.
¹⁸ HLA Laboratory, CHU Brest, Brest, France.
¹⁹ HLA Laboratory, CHU Toulouse, Toulouse, France.
²⁰ HLA Laboratory, CHU Nice, Nice, France.
²¹ HLA Laboratory, AP-HP Paris Pitié Salpetrière, Paris, France.
²² HLA Laboratory, EFS Rouen, Rouen, France.
²³ HLA Laboratory, EFS Caen, Caen, France.
²⁴ HLA Laboratory, AP-HP Paris Robert Debré, Paris, France.
²⁵ HLA Laboratory, AP-HP Paris Necker, Paris, France.
²⁶ Registre France Greffe de Moelle (RFGM), Saint Denis La Plaine, France.
²⁷ Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hematology Department, University Hospital, Lille, France.
²⁸ 1] HLA Laboratory, EFS Nantes, Nantes, France [2] Labex Transplantex, Université Strasbourg, Strasbourg, France.

PMID: 25365066
DOI: 10.1038/bmt.2014.253

Abstract

We retrospectively analyzed the impact of HLA-DPB1 mismatches in a large cohort of 1342 French patients who underwent 10/10 HLA-matched unrelated HSCT. A significant impact of HLA-DPB1 allelic mismatches (2 vs 0) was observed in severe acute GVHD (aGVHDIII-IV) (risk ratio (RR)=1.73, confidence interval (CI) 95% 1.09-2.73, P=0.019) without impact on OS, TRM, relapse and chronic GVHD (cGVHD). According to the T-cell epitope 3 (TCE3)/TCE4 HLA-DPB1 disparity algorithm, 37.6% and 58.4% pairs had nonpermissive HLA-DPB1, respectively. TCE3 and TCE4 disparities had no statistical impact on OS, TRM, relapse, aGVHD and cGVHD. When TCE3/TCE4 disparities were analyzed in the graft-vs-host or host-vs-graft (HVG) direction, only a significant impact of TCE4 nonpermissive disparities in the HVG direction was observed on relapse (RR=1.34, CI 95% 1.00-1.80, P=0.048). In conclusion, this French retrospective study shows an adverse prognosis of HLA-DPB1 mismatches (2 vs 0) on severe aGVHD and of nonpermissive TCE4 HVG disparities on relapse after HLA-matched 10/10 unrelated HSCT.

Publication types

Clinical Trial
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Algorithms*
Allografts
Child
Child, Preschool
Female
France
Graft vs Host Disease / mortality
Graft vs Host Disease / prevention & control
HLA-DP beta-Chains*
Hematologic Neoplasms / mortality
Hematologic Neoplasms / therapy*
Hematopoietic Stem Cell Transplantation*
Host vs Graft Reaction
Humans
Male
Middle Aged
Unrelated Donors*

Substances

HLA-DP beta-Chains
HLA-DPB1 antigen